Company: DVAX
Filing Date: 2025-04-03
Form Type: PREC14A
Source: 0000930413-25-001153
Chunk: 91

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-03
Form: PREC14A
Chunk 91
---
 |     | $            | 62,091 |     | $               | 2,927,743 |     | $     |  4,650,537 |
| John L. Slebir       |     | $         | 1,192,500 |     | $            | 56,312 |     | $               | 1,937,054 |     | $     |  3,185,866 |
| Robert Janssen, M.D. |     | $         | 1,220,155 |     | $            | 39,492 |     | $               | 1,505,814 |     | $     |  2,765,461 |

| (1) | Represents the value of accelerated vesting of equity awards assuming the event took place on December 31,                   
 2024. The value for RSUs (including PSUs) is calculated based on the closing price per share on December 31, 2024. The value 
 for stock option awards is calculated based on the “spread” between the closing price per share on December 31,              
 2024 of $12.77 and the exercise price of the vested awards, to the extent such vested awards were “in the money.”            |

Qualifying Termination Not in Connection with a Change in Control.

Under the terms of the Management Agreements, upon an “involuntary”
termination without “cause” (and other than due to death or disability) or, if applicable, upon a resignation for “good
reason” (each as defined above), the NEO will, subject to the execution of a release of claims, be entitled to receive:

| • | a lump-sum cash payment equal to the specified number of months (18 months for Mr. Spencer, 15 months for Mr. Novack and   
 12 months for our other NEOs) of the executive’s then-effective annual base salary;                                        |
| • | the COBRA Payment;                                                                                                         |
| • | a lump-sum cash payment equal to the NEO’s target annual variable cash compensation for the year of termination, pro-rated 
 as of the date of termination;                                                                                             |

| 72 |

| • | the acceleration of vesting of time-vesting stock options to purchase the Company’s common stock for a specified number              
 of months (18 months for Mr. Spencer, 15 months for Mr. Novack and 12 months for our other NEOs) following termination of